US 12,472,257 B2
Pharmaceutical compositions comprising meloxicam
Herriot Tabuteau, New York, NY (US)
Assigned to Axsome Therapeutics, Inc., New York, NY (US)
Filed by AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed on Jun. 4, 2025, as Appl. No. 19/228,565.
Application 19/228,565 is a continuation of application No. 18/582,561, filed on Feb. 20, 2024.
Application 18/582,561 is a continuation of application No. 18/185,477, filed on Mar. 17, 2023, granted, now 11,944,683, issued on Apr. 2, 2024.
Application 18/185,477 is a continuation of application No. 17/656,602, filed on Mar. 25, 2022, granted, now 11,617,791, issued on Apr. 4, 2023.
Application 17/656,602 is a continuation in part of application No. 17/325,616, filed on May 20, 2021, granted, now 11,285,215, issued on Mar. 29, 2022.
Application 17/325,616 is a continuation of application No. 17/024,233, filed on Sep. 17, 2020, granted, now 11,020,483, issued on Jun. 1, 2021.
Application 17/024,233 is a continuation of application No. 16/867,929, filed on May 6, 2020, granted, now 10,821,182, issued on Nov. 3, 2020.
Application 16/867,929 is a continuation in part of application No. 16/689,970, filed on Nov. 20, 2019, granted, now 10,688,185, issued on Jun. 23, 2020.
Application 16/689,970 is a continuation in part of application No. 16/454,319, filed on Jun. 27, 2019, granted, now 10,512,693, issued on Dec. 24, 2019.
Application 16/454,319 is a continuation in part of application No. 16/248,449, filed on Jan. 15, 2019, granted, now 10,363,312, issued on Jul. 30, 2019.
Application 16/248,449 is a continuation of application No. 15/986,215, filed on May 22, 2018, granted, now 10,195,278, issued on Feb. 5, 2019.
Application 15/986,215 is a continuation of application No. 15/984,055, filed on May 18, 2018, granted, now 10,265,399, issued on Apr. 23, 2019.
Claims priority of provisional application 62/536,466, filed on Jul. 25, 2017.
Claims priority of provisional application 62/526,884, filed on Jun. 29, 2017.
Prior Publication US 2025/0295783 A1, Sep. 25, 2025
Int. Cl. A61K 31/5415 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/4196 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/40 (2006.01); A61K 47/69 (2017.01); A61P 25/06 (2006.01); C08B 37/16 (2006.01)
CPC A61K 47/02 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 31/4196 (2013.01); A61K 31/4439 (2013.01); A61K 31/5415 (2013.01); A61K 45/06 (2013.01); A61K 47/40 (2013.01); A61K 47/6951 (2017.08); A61P 25/06 (2018.01); C08B 37/0012 (2013.01); C08B 37/0015 (2013.01)] 20 Claims
 
1. A method of rapidly delivering meloxicam to the blood of a human being comprising orally administering a solid dosage form to a human being in need of treatment of pain, wherein the dosage form comprises meloxicam and a bicarbonate, wherein the bicarbonate is present in the dosage form in an amount of between 50 mg to 250 mg or 350 mg to 850 mg, and wherein the solid dosage form provides a Tmax of meloxicam in the human being that is less than 4 hours.